Harrigan PR - Search Results

1

Differential escape patterns within the dominant HLA-B*57:03-restricted HIV Gag epitope reflect distinct clade-specific functional constraints.

Payne RP, Branch S, Kløverpris H, Matthews PC, Koofhethile CK, Strong T, Adland E, Leitman E, Frater J, Ndung'u T, Hunter E, Haubrich R, Mothe B, Edwards A, Riddell L, Chen F, Harrigan PR, Brumme ZL, Mallal S, John M, Jooste JP, Shapiro R, Deeks SG, Walker BD, Brander C, Landis C, Carlson JM, Prado JG, Goulder PJ. Payne RP, et al. Among authors: harrigan pr. J Virol. 2014 May;88(9):4668-78. doi: 10.1128/JVI.03303-13. Epub 2014 Feb 5. J Virol. 2014. PMID: 24501417 Free PMC article.

2

Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.

Côté HC, Brumme ZL, Harrigan PR. Côté HC, et al. Among authors: harrigan pr. J Virol. 2001 Jan;75(2):589-94. doi: 10.1128/JVI.75.2.589-594.2001. J Virol. 2001. PMID: 11134271 Free PMC article.

3

CCR5Delta32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response.

Brumme ZL, Chan KJ, Dong W, Hogg R, O'Shaughnessy MV, Montaner JS, Harrigan PR. Brumme ZL, et al. Among authors: harrigan pr. AIDS. 2001 Nov 23;15(17):2259-66. doi: 10.1097/00002030-200111230-00007. AIDS. 2001. PMID: 11698699

4

Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.

Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JM, Pennington KN, St Clair MH. Larder BA, et al. Among authors: harrigan pr. J Virol. 1996 Sep;70(9):5922-9. doi: 10.1128/JVI.70.9.5922-5929.1996. J Virol. 1996. PMID: 8709213 Free PMC article. Clinical Trial.

5

Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.

Harrigan PR, Kinghorn I, Bloor S, Kemp SD, Nájera I, Kohli A, Larder BA. Harrigan PR, et al. J Virol. 1996 Sep;70(9):5930-4. doi: 10.1128/JVI.70.9.5930-5934.1996. J Virol. 1996. PMID: 8709214 Free PMC article.

6

Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.

Harrigan PR, Miller MD, McKenna P, Brumme ZL, Larder BA. Harrigan PR, et al. Antimicrob Agents Chemother. 2002 Apr;46(4):1067-72. doi: 10.1128/AAC.46.4.1067-1072.2002. Antimicrob Agents Chemother. 2002. PMID: 11897591 Free PMC article.

7

Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.

Harrigan PR, Bloor S, Larder BA. Harrigan PR, et al. J Virol. 1998 May;72(5):3773-8. doi: 10.1128/JVI.72.5.3773-3778.1998. J Virol. 1998. PMID: 9557659 Free PMC article.

8

A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine.

Kemp SD, Shi C, Bloor S, Harrigan PR, Mellors JW, Larder BA. Kemp SD, et al. Among authors: harrigan pr. J Virol. 1998 Jun;72(6):5093-8. doi: 10.1128/JVI.72.6.5093-5098.1998. J Virol. 1998. PMID: 9573280 Free PMC article.

9

Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide.

Loutfy MR, Raboud JM, Montaner JS, Antoniou T, Wynhoven B, Smaill F, Rouleau D, Gill J, Schlech W, Brumme ZL, Mo T, Gough K, Rachlis A, Harrigan PR, Walmsley SL. Loutfy MR, et al. Among authors: harrigan pr. Antiviral Res. 2007 Jul;75(1):58-63. doi: 10.1016/j.antiviral.2006.11.011. Epub 2006 Dec 18. Antiviral Res. 2007. PMID: 17196268

10

Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.

Harrigan PR, Stone C, Griffin P, Nájera I, Bloor S, Kemp S, Tisdale M, Larder B. Harrigan PR, et al. J Infect Dis. 2000 Mar;181(3):912-20. doi: 10.1086/315317. J Infect Dis. 2000. PMID: 10720512

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

321 results

Search Page

Filters